Journal
CHEMICAL COMMUNICATIONS
Volume 57, Issue 3, Pages 367-370Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0cc03399e
Keywords
-
Categories
Ask authors/readers for more resources
The study presented a novel immunosensor for the quantitative and selective detection of ADAs against a drug, which may enhance the effectiveness of clinical treatment.
The efficacy of immunotherapy can be undermined by the development of an immune response against a drug/antibody mediated by anti-drug antibodies (ADAs) in treated patients. We present the first label-free EGOFET immunosensor that integrates a biological drug, Nivolumab (Opdivo (c)), as a specific recognition moiety to quantitatively and selectively detect ADAs against the drug. The limit of detection is 100 fM. This demonstration is a prelude to the detection of ADAs in a clinical setting in the treatment of different pathologies, and it also enables rapid screening of biological drugs for immunogenicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available